scholarly journals Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era

2020 ◽  
Vol 40 (10) ◽  
pp. 2407-2416
Author(s):  
Oluwaseun Falade‐Nwulia ◽  
Rachel E. Gicquelais ◽  
Jacquie Astemborski ◽  
Sean D. McCormick ◽  
Greg Kirk ◽  
...  
Keyword(s):  
Hepatitis C ◽  
People Who Inject Drugs ◽  
Hepatitis C Treatment ◽  
Direct Acting Antiviral ◽  
Treatment Uptake ◽  
Direct Acting

scholarly journals Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Stelliana Goutzamanis ◽  
Danielle Horyniak ◽  
Joseph S. Doyle ◽  
Margaret Hellard ◽  
Peter Higgs ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Physical Health ◽  
Antiviral Treatment ◽  
Health Benefits ◽  
Community Treatment ◽  
Physical And Mental Health ◽  
Structured Interviews ◽  
Direct Acting Antiviral ◽  
Treatment Uptake ◽  
Direct Acting

Abstract Background Novel health promotion and treatment uptake initiatives will be necessary to ensure Australia meets 2030 hepatitis C elimination targets. Increasing treatment uptake will be assisted by a better understanding of the treatment experience and patient-perceived benefits. This study describes the perceived physical health benefits from direct-acting antiviral (DAA) hepatitis C treatment among people who inject drugs in Melbourne, Australia. Methods Twenty participants were recruited from a community treatment trial and community health clinics. Semi-structured interviews were performed with each participant before, during and following treatment. Interviews focused on treatment experiences, attitudes and motivations. Interviews were recorded, transcribed and thematically analysed. Results Two themes relating to the physical experience of treatment developed; intersection between physical and mental health and “maybe it’s working”. Participants reported various physical benefits, most prominently, reduced fatigue. Reductions in fatigue resulted in instant and meaningful changes in everyday life. Some participants did experience side effects, which they described as mild. Experiencing noticeable physical benefits during treatment was perceived as validation that treatment was working. Conclusion Physical health benefits of DAA treatment may have carry-on effects on cognitive, emotional or social wellbeing and should be incorporated into how treatment is promoted to those who require it.

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case

2016 ◽  
Vol 23 (10) ◽  
pp. 767-779 ◽  
Author(s):  
S. Deuffic-Burban ◽  
D. Obach ◽  
V. Canva ◽  
S. Pol ◽  
F. Roudot-Thoraval ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hepatitis C ◽  
Budget Impact ◽  
Hepatitis C Treatment ◽  
Direct Acting Antiviral ◽  
French Case ◽  
Direct Acting

scholarly journals Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy

2019 ◽  
Vol 70 (12) ◽  
pp. 2695-2702 ◽  
Author(s):  
Matthew J Akiyama ◽  
Daniel Lipsey ◽  
Moonseong Heo ◽  
Linda Agyemang ◽  
Brianna L Norton ◽  
...  
Keyword(s):  
Hepatitis C ◽  
People Who Inject Drugs ◽  
Controlled Trial ◽  
Extension Study ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Direct Acting Antiviral ◽  
Opioid Agonist Therapy ◽  
Direct Acting

Abstract Background Direct-acting antiviral (DAA) therapy is highly effective in people who inject drugs (PWID); however, rates, specific injection behaviors, and social determinants associated with hepatitis C virus (HCV) reinfection following DAA therapy among PWID on opioid agonist therapy (OAT) are poorly understood. Methods PREVAIL was a randomized controlled trial that assessed models of HCV care for 150 PWID on OAT. Those who achieved sustained virologic response (SVR) (n = 141; 94%) were eligible for this extension study. Interviews and assessments of recurrent HCV viremia occurred at 6-month intervals for up to 24 months following PREVAIL. We used survival analysis to analyze variables associated with time to reinfection. Results Of 141 who achieved SVR, 114 had a least 1 visit in the extension study (62% male; mean age, 52 years). Injection drug use (IDU) was reported by 19% (n = 22) in the extension study. HCV reinfection was observed in 3 participants. Over 246 person-years of follow-up, the incidence of reinfection was 1.22/100 person-years (95% CI, 0.25–3.57). All reinfections occurred among participants reporting ongoing IDU. The incidence of reinfection in participants reporting ongoing IDU (41 person-years of follow-up) was 7.4/100 person-years (95% CI, 1.5–21.6). Reinfection was associated with reporting ongoing IDU in the follow-up period (P < .001), a lack confidence in the ability to avoid contracting HCV (P < .001), homelessness (P = .002), and living with a PWID (P = .007). Conclusions HCV reinfection was low overall, but more common among people with ongoing IDU following DAA therapy on OAT, as well as those who were not confident in the ability to avoid contracting HCV, homeless, or living with a PWID. Interventions to mediate these risk factors following HCV therapy are warranted.

scholarly journals Hepatitis C Resistance-Associated Variants Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Matthew Akiyama ◽  
Jacqueline Reeves ◽  
Yolanda Lie ◽  
Linda Agyemang ◽  
Alain Litwin
Keyword(s):  
Hepatitis C ◽  
People Who Inject Drugs ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals NON-ADHERENCE TO HEPATITIS C TREATMENT: A BRAZILIAN REPORT

2021 ◽  
Vol 58 (4) ◽  
pp. 456-460
Author(s):  
Claudia Alexandra Pontes IVANTES ◽  
Bernardo Carvalho da SILVA ◽  
Gabriel Gonçalves ACOSTA ◽  
Fabiane Beatriz Neves El TAWIL ◽  
Renato NISIHARA
Keyword(s):  
Public Health ◽  
Hepatitis C ◽  
Health System ◽  
Public Health System ◽  
Epidemiological Data ◽  
Hepatitis C Treatment ◽  
The Public ◽  
Direct Acting Antiviral ◽  
Private Medicine ◽  
Direct Acting

ABSTRACT BACKGROUND: In Brazil, since 2015, the treatment of hepatitis C is provided by SUS (Public Health System) with direct-acting antiviral (DAA). OBJECTIVE: To describe the rate of non-adherence patients to hepatitis C treatment by DAA, investigating the epidemiological data in a large database from Curitiba, Brazil. METHODS: Retrospective study with patients treated between January 2015 and June 2019. Patients were considered adherent when received all medication doses during their treatment. The following data were evaluated: gender, age, type of treatment, period of treatment, presence of diabetes or HIV, previous therapy, originated from SUS or private medicine, fibrosis grade and HCV genotype. RESULTS: 1248 patients (56.8% males) were studied and 102/1248 (8.2%) were non-adherent to treatment. Age or gender not influenced significantly; 10.2% patients from SUS and 3.7% individuals from private medicine were non-adherent (P<0.0001; OR=2.9; CI95%=1.6-9.1); 13.1% patients were co-infected with HIV and among them, 15.9% abandoned treatment. Individuals without co-infection presented 7.0% of non-adherence (P<0.0001; OR=2.5; CI=1.5-4.1). All the other variables showed no differences in the adhesion rate. CONCLUSION: Our study showed that 8.2% of patients were non-adherent to HCV treatment, and that patients from the Public Health System and co-infected with HIV were significantly less adherent.

scholarly journals Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated with Direct-Acting Antiviral-Containing Regimens

2021 ◽  
Author(s):  
Matthew J Akiyama ◽  
Lindsey Riback ◽  
Jacqueline D Reeves ◽  
Yolanda S Lie ◽  
Linda Agyemang ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Protease Inhibitor ◽  
People Who Inject Drugs ◽  
Virologic Failure ◽  
Late Relapse ◽  
Resistant Virus ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Background Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) can contribute to virologic failure and limit retreatment options. People who inject drugs (PWID) are at highest risk for transmission of resistant virus. We report on RASs at baseline and following virologic failure in DAA-naive and protease inhibitor-experienced PWID. Methods We sequenced the NS3/4A, NS5A, and NS5B regions from 150 PWID with genotype 1 (GT1) viruses; 128 (85.3%) GT1a, 22 (14.7%) GT1b. Results Among the 139 (92.7%) DAA-naive PWID, 85/139 (61.2%) had baseline RASs – 67/139 (48.2%) in NS3 (predominantly Q80K/L); 25/139 (18.0%) in NS5A; and 8/139 (5.8%) in NS5B. Of the 11 protease inhibitor-experienced participants, 9 had baseline NS3 RASs (V36L N=1, Q80K N=9) and 4 had baseline NS5A RASs (M28V N=2, H58P N=1, A92T N=1). Among the 11 participants who had post-treatment samples with detectable virus (seven treatment failures, one late relapse, three reinfections), one sofosbuvir/ledipasvir failure had a baseline H58P. Two sofosbuvir/ledipasvir-treated participants developed new NS5A mutations (Q30H, Y93H, L31M/V). Otherwise, no RASs were detected. Conclusion Our results demonstrate RAS prevalence among DAA-naive PWID is comparable to that in the general population. Only 2/150 (1.3%) in our longitudinal cohort developed treatment-emergent RASs. Concern for transmission of resistant virus may therefore be minimal.

Sign in / Sign up

Export Citation Format

Share Document